Title: Shrinkage of Thyroid Volume in Sunitinib-Treated Patients with Renal-Cell Carcinoma: A Potential Marker of Irreversible Thyroid Dysfunction?
Authors: Rogiers, Aljosja ×
Wolter, Pascal
Op de beeck, Katya
Thijs, Marleen
Decallonne, Brigitte
Schöffski, Patrick #
Issue Date: Mar-2010
Publisher: Mary Ann Liebert Publishers
Series Title: Thyroid vol:20 issue:3 pages:317-322
Abstract: Background: The multitargeted tyrosine kinase inhibitor sunitinib is known to induce thyroid dysfunction in a substantial proportion of patients treated for advanced renal-cell carcinoma or gastrointestinal stromal tumors. Although sunitinib-induced hypothyroidism seems to be reversible in the majority of patients, some patients develop irreversible thyroid damage resulting in long-lasting thyroid hormone replacement therapy.
ISSN: 1050-7256
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Experimental Oncology
Clinical and Experimental Endocrinology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science